Texas Dermatology and Laser Specialists
Welcome,         Profile    Billing    Logout  
 43 Trials 
270 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smith, Scott E
NCT05296525: Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL

Terminated
1/2
13
US
GDA-201, NAM NK
Gamida Cell ltd
Non-Hodgkin Lymphoma
04/24
04/24
Woolery-Lloyd, Heather
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
Rosso, James Q Del
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Recruiting
3
726
US, RoW
Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Alopecia, Androgenetic
10/24
04/25
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
Boyce, Brent
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
Stough, Dowling B
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
HZNP-DAX-201, NCT05368103: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Completed
2
30
Canada, US
Daxdilimab, HZN-7734
Amgen
Alopecia Areata
08/23
01/24
Browning, John C
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
NCT05084508 / 2022-001910-21: A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Completed
2
800
Europe, US, RoW
Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Marketed varicella vaccine Lot 1, Marketed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
GlaxoSmithKline, GlaxoSmithKline Biologicals SA (GSK)
Chickenpox
02/24
06/24
Dawes, Kenneth W
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
HZNP-DAX-201, NCT05368103: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Completed
2
30
Canada, US
Daxdilimab, HZN-7734
Amgen
Alopecia Areata
08/23
01/24
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
NCT06603220: A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria

Recruiting
2
30
US
Oral EVO756
Evommune, Inc.
Chronic Inducible Urticaria
03/25
04/25
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
154
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
06/25
07/25
NCT03827798 / 2018-002757-30: Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting
2
248
Europe, US, RoW
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Novartis Pharmaceuticals
Hidradenitis Suppurativa
12/24
12/26
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Guenthner, Scott
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Recruiting
3
165
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
09/25
06/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
HZNP-DAX-201, NCT05368103: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Completed
2
30
Canada, US
Daxdilimab, HZN-7734
Amgen
Alopecia Areata
08/23
01/24
EASE, NCT06144424: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Completed
2
32
Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Atopic Dermatitis
07/24
07/24
Gold, Linda Stein
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Recruiting
3
726
US, RoW
Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Alopecia, Androgenetic
10/24
04/25
Tu, John H
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Active, not recruiting
3
186
US
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Superficial Basal Cell Carcinoma
03/24
02/29
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Recruiting
3
165
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
09/25
06/26
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
NCT05080764: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Recruiting
2
126
US
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Acne Vulgaris
02/25
02/25
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Completed
1
112
US
BF-200 ALA and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratosis, Keratosis, Actinic, Keratosis
04/23
04/23
Hull, Cheryl
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
Forsha, Douglass W
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Active, not recruiting
3
186
US
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Superficial Basal Cell Carcinoma
03/24
02/29
EASE, NCT06144424: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Completed
2
32
Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Atopic Dermatitis
07/24
07/24
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
BMX-DERM-02, NCT05491447: A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Terminated
2
103
US
BMX-010, Placebo
BioMimetix JV, LLC, Innovaderm Research Inc.
Atopic Dermatitis
12/23
04/24
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
Sofen, Howard
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
360
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical Corticosteroid (TCS)
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
02/26
02/27
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/24
08/29
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
310
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
BRAVE-AA1, NCT03570749: A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Checkmark Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Apr 2021 - Apr 2021: Efficacy and safety data from BRAVE-AA1 trial in adults with severe alopecia areata
Checkmark From BRAVE-AA1 trial for alopecia areata
Oct 2020 - Oct 2020: From BRAVE-AA1 trial for alopecia areata
Active, not recruiting
2/3
824
Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company, Incyte Corporation
Alopecia Areata
02/21
01/25
AMETHYST, NCT05531565 / 2020-000727-40: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Recruiting
2/3
474
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen, Biogen Idec Research Limited
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
10/26
12/27
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
NCT06602219: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
2
220
Canada, Japan, US
LY4100511, Placebo
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Plaque Psoriasis
07/25
08/25
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
Zaenglein, Andrea L
NCT05080764: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Recruiting
2
126
US
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Biofrontera Bioscience GmbH
Acne Vulgaris
02/25
02/25
Waibel, Jill
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
BALLAD+, NCT05681481 / 2021-003063-10: A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants with Bullous Pemphigoid

Active, not recruiting
3
160
Europe, Japan, US, RoW
efgartigimod PH20 SC, Prednisone
argenx, argenx BV
Bullous Pemphigoid
01/26
03/26
NCT04877756: Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

Completed
2
22
US
OLX10010, a cell penetrating asymmetric small interference RNA (cp-asiRNA), targeting a gene involved in formation of fibrosis
Olix Pharmaceuticals, Inc., Alira Health
Hypertrophic Scar
01/23
07/23
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Recruiting
2
117
US, RoW
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Lutris Pharma Ltd.
EGFRI Induced Acneiform Lesions
03/24
05/24
RECAST DLE, NCT05591222 / 2022-000831-21: Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus

Active, not recruiting
2
72
Europe, Canada, US, RoW
Placebo/Daxdilimab, Daxdilimab, HZN-7734
Amgen, Horizon Therapeutics Ireland DAC
Discoid Lupus Erythematosus
09/25
09/25
NCT05171894: A Study to Evaluate Efficacy and Safety of Light Dose in Subjects with PWB Treated with Hemoporfin PDT

Recruiting
2
84
US
Hemopfin+Green Light, Hemopfin photodynamic therapy, Vehicle+Green Light, saline photodynamic therapy
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
01/26
04/26
Sculptra, NCT05620043: Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler

Completed
N/A
21
US
Sculptra, Radiesse Plus
Galderma R&D
Gene Expression
07/23
11/23
Smith, Shondra
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Active, not recruiting
3
120
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
Contact, Site Public
NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed
4
50
RoW
ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Hemophilia A
02/23
02/23
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed
4
4
US
Digital Engagement Application (GD App), No Intervention
Takeda
Gaucher Disease
02/23
02/23
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
TAK-665-4001, NCT05058391 / 2022-004193-39: A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed
4
5
RoW
Elaprase, Idursulfase
Takeda, Takeda Biopharmaceuticals India Pvt. Ltd.
Hunter Syndrome
04/24
04/24
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
08/24
08/24
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting
4
5
RoW
Replagal
Shire
Fabry Disease
10/26
11/26
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting
4
50
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
03/26
03/26
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
07/28
07/28
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
51
Europe, Japan, US
BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Active, not recruiting
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Terminated
3
1
Europe
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
08/24
08/24
NCT04974749 / 2022-004246-35: A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Completed
3
20
RoW
REPLAGAL, Agalsidase Alfa, TAK-675
Takeda, Takeda Development Center Americas, Inc
Fabry Disease
01/24
01/24
NCT05460325 / 2023-001105-31: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed
3
20
RoW
Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection
Takeda, Takeda
Hereditary Angioedema (HAE)
11/23
11/23
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Recruiting
3
30
Europe, RoW
Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy
Takeda
Pouchitis
12/29
12/29
NCT06060067 / 2023-000134-15: A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Active, not recruiting
3
480
RoW
TDV, TAK-003, Placebo
Takeda, Takeda
Healthy Volunteers
05/25
05/25
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
NCT05529992 / 2022-002323-35: A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Completed
3
20
RoW
Velaglucerase Alfa, VPRIV
Takeda, Takeda
Gaucher Disease
08/24
08/24
 

Download Options